OphthaNova Therapeutics AG

About the company OphthaNova Therapeutics AG

OphthaNova Therapeutics AG, based in Schlieren, is a company in Switzerland. OphthaNova Therapeutics AG is active according to the commercial register. The company with the UID number CHE-485.039.892 was founded on 08/19/2025.

For OphthaNova Therapeutics AG, a total of 1 official reports from the Swiss Official Gazette (SOGC) have been published on shab.help.ch since January 2007. You can see the latest publication by company OphthaNova Therapeutics AG from 08/22/2025 on this link.

Purpose of the company OphthaNova Therapeutics AG

The purpose of the company OphthaNova Therapeutics AG in Schlieren is as follows. The company's purpose is the development of biopharmaceutical products, particularly in the field of ophthalmology, and grants corresponding licenses. The company may enter into all transactions and conclude contracts that may be related to the company's purpose. The company may establish branches and subsidiaries in Switzerland and abroad and participate in other companies in Switzerland and abroad. The company may acquire, hold, manage, encumber, exploit, and dispose of real estate and intellectual property rights in Switzerland and abroad, as well as finance other companies. The company may carry out all commercial, financial, and other activities that appear suitable to promote the company's purpose or that are related to it.

Translated by google.com

The company OphthaNova Therapeutics AG in Schlieren is listed on Yellowpages.swiss. Latitude and longitude coordinates for OphthaNova Therapeutics AG are: 47.3992547 and 8.4602253. The unique identification number of this portrait is CHE-485.039.892.

---

Data Source: Commercial register, SOGC, FSO
Last update on 22.08.2025

Which companies are available at the same address? In addition to OphthaNova Therapeutics AG, there are other active companies at the same address Wagistrasse 27, 8952 Schlieren. This includes the companies hemotune AG| PharmaBiome AG| NovaGo Therapeutics AG.